2 Natural history studies of familial hypercholesterolemia (FH), a genetic disorder associated with elevated cholesterol and premature coronary artery disease, and with a frequency of about 1:500 in the general population, were first conducted in the 1970s. 1 Homozygotes, with cholesterol levels in excess of 500 mg/dl experience coronary events as early as adolescence and heterozygotes (with one normal and one abnormal gene) are affected prematurely in middle age. The first major breakthrough in understanding the disease came with the discovery of the low density lipoprotein (LDL) receptor by Brown and Goldstein, work that won the Nobel prize. 2 Over the last 20 or so years, several hundred separate defects have been identified as causes of elevated LDL cholesterol via alteration of function of the LDL receptor.
These defects fall into several groups. Most common are defects of receptor function ranging from the absence of receptor expression (the most severe) to abnormalities in receptor function. The second most common group are defects in the formation of apolipoprotein B, the major protein on LDL, so that binding of the protein to the receptor is impaired. 3 Finally, genes related to the regulation of LDL receptor function have recently been uncovered, PCSK9 is important in this process, and defects that impair receptor function increase LDL levels and risk for heart disease while those that enhance LDL receptor function lower the risk for heart disease. 4 In Europe, genotyping of patients suspected of having FH is common and a genetic defect is identified at least 80% of the time. where natural history studies of statin treatment have been underway for many years, it is highly likely that the benefits of LDL lowering for coronary artery disease prevention in this disease will be conclusively established. A second advance will likely be the incorporation of genetic testing into standard clinical practice to diagnose FH and risk stratify based on the particular genetic defect. Future research should also be directed towards understanding whether clinicians should be satisfied with substantial cholesterol lowering from low to moderate statin dosing or if it will be necessary to achieve specific LDL target levels to achieve prevention of events. Safety evaluations will be critical in these trials.
Research to date has allowed the United Kingdom to develop cholesterol lowering guidelines specific for FH, the NICE guidelines. 12 This approach is different than the approach in the United States that is linked specifically to LDL cholesterol levels and not to the diagnosis of FH. Cost benefit analysis has shown that the combination of genotype screening of potentially affected individuals and subsequent lipid lowering therapy of affected individuals is justified. Perhaps the time has come in the United States to separate out those individuals with known high risk for premature coronary artery disease from more general population-based guidelines. This may allow for the development of clinical trials specifically directed towards these high risk patients, those with FH, diabetes mellitus, and multiple risk states created by interactions of genetics with obesity and/or tobacco use.
